{
  "id": 16485991,
  "title": "After a long, strange trip, this CEO is close to taking a psilocybin pill to market",
  "url": "https://urgent.news/2026/10/25/after-a-long-strange-trip-this-ceo-is-close-to-taking-a-psilocybin",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-25T14:07:08.000Z",
  "source": {
    "name": "Business Insider",
    "slug": "business-insider",
    "url": "https://www.businessinsider.com/compass-ceo-kabir-nath-psilocybin-pill-comp360-psychedelics-2026-10"
  },
  "original_language": "en",
  "account": "Kabir Nath, CEO of Compass Pathways, is on the brink of bringing a psilocybin pill to market. The company aims to use the drug to treat treatment-resistant depression. Nath, a former executive at a pharmaceutical firm, joined Compass Pathways after receiving a call from a company with a patent on synthetic psilocybin. Nath, who lost his father to suicide, was the first senior executive from traditional pharma to move to the psychedelic field. The company has recently expanded its marketing division and relocated to Jersey City, hiring 150 new employees. Compass has received breakthrough therapy designation from the FDA, but approval is not guaranteed. If denied, the company could face bankruptcy. Nath describes the psilocybin pill, COMP360, as a quiet room with a couch, blindfold, and a playlist of music. The drug is intended for patients with treatment-resistant depression, who have failed to respond to two or more standard drugs.",
  "summary": "Compass Pathways is on the cusp of FDA approval for a proprietary version of psilocybin — the active drug in magic mushrooms.",
  "key_points": [
    "Kabir Nath, Compass Pathways CEO, nears psilocybin pill launch",
    "Drug COMP360 for treatment-resistant depression, not FDA-approved yet",
    "Nath former pharma exec, moved to psychedelics after father's suicide"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}